Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct:159:33-34.
doi: 10.1016/j.pediatrneurol.2024.07.017. Epub 2024 Jul 30.

Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion

Affiliations
Editorial

Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion

Omer Abdul Hamid et al. Pediatr Neurol. 2024 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest O.A.H. has received compensation for ad hoc advisory boards with PTC therapeutics, Sarepta, Catalyst, and Percheron and speaker's bureau for Biogen and Genentech. S.E.M. has received compensation for ad hoc advisory boards/consulting for Sarepta, Novartis, and Atamyo Therapeutics. S.W. has received compensation for advisory boards for Sarepta. K.Y.B. has received compensation for consulting/advisory role with Biogen, UCB, Reata Pharmaceuticals, Pfizer, Catalyst Pharmaceuticals, and MyTomorrows. C.M.P. has received honoraria for advisory board participation from Biogen, Novartis, Roche, and Sarepta and speaker's fees from Biogen and Novartis. A.V. has received compensation for ad hoc advisory boards/consulting activity with Biogen, Novartis, AveXis, Sarepta, PTC, Scholar Rock, Fibrogen, AMO, Pfizer, Catalyst, Lupin, Entrada, MyTomorrows, Percheron, and Italfarmaco.

Publication types

MeSH terms

LinkOut - more resources